Skip to main content
. 2023 Dec 13;36:100792. doi: 10.1016/j.lanepe.2023.100792

Fig. 2.

Fig. 2

Least proportion (%) of prevalence of chronic hepatitis C virus (HCV) infection (cHCV) that is attributed to injection drug use in the European Union—European Economic Area (EU/EEA). Notes: HCV-RNA prevalence is used as a proxy for cHCV; Population: 15–79 years old.